This Phase 1 study tests a new T cell therapy for children and adults with EBV-positive Hodgkin or non-Hodgkin lymphoma, or T/NK-cell lymphoproliferative disease.
Description
Epstein-Barr virus (EBV) is a common virus that can be linked to certain types of cancer, including Hodgkin and non-Hodgkin lymphoma. In some patients, EBV is found in the cancer cells, helping them hide from the immune system. This study is testing a new treatment using EBV-specific T cells, which are special immune cells trained to find and kill EBV-infected cancer cells. To make these cells stronger and last longer in the body, researchers added a gene called C7R, which helps the cells survive by giving them a steady supply of a substance called cytokine. The goal is to find the safest dose of these modified T cells and see how well they work against cancer. Patients may also receive standard chemotherapy before the T cell infusion to help the cells grow better. Researchers will monitor how long the T cells stay in the body and how they affect the cancer. This study includes long-term follow-up and blood tests to understand how the treatment works. It may also involve collecting tumor samples for research.
Eligibility
Children and adults of any age
Diagnosis of EBV-positive Hodgkin lymphoma, non-Hodgkin lymphoma, or T or NK cell lymphoproliferative disease
Relapsed, persistent, or active disease
Adequate organ function
Karnofsky/Lansky score ≥ 50
Off other investigational therapies for at least 4 weeks
Detailed inclusion and exclusion criteria are listed at clinicaltrials.gov.
To inquire about this trial, fill out our online referral form:
